COMMUNIQUÉS West-GlobeNewswire

Results of the Combined General Meeting of 28 June 2024
28/06/2024
Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial [...]
Résultats de l'Assemblée Générale Mixte du 28 juin 2024
28/06/2024
Lyon (France) et Cambridge (MA, US), le 28 juin 2024 – 17h45 CEST – PHAXIAM Therapeutics (Euronext : PHXM ; FR0011471135) société biopharmaceutique qui développe des traitements innovants contre les infections [...]
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
28/06/2024
Allschwil, Switzerland – June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in [...]
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
28/06/2024
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve [...]
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
28/06/2024
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
Zealand Pharma major shareholder announcement: Van Herk Investments
28/06/2024
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a [...]
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
28/06/2024
Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), [...]
Tiziana Receives $3.4 Million in Non-Dilutive Funding
28/06/2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to [...]
Hapbee Announces Launch of Hapbee Experience At Irish Pub in Partnership with BodyTonic
28/06/2024
Shareholders Elect Two New Directors Following Recent Annual General Meeting VANCOUVER, British Columbia, June 28, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB ) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or [...]
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
28/06/2024
Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccine Emergency Use Authorization for the MVA-BN vaccine has been issued in the [...]
YorkTest Announces Limited–Time Offer to Enhance Accessibility of At-Home Health Testing
28/06/2024
WILMINGTON, Del., June 28, 2024 (GLOBE NEWSWIRE) -- YorkTest has launched a new offer to make at-home food sensitivity and allergy testing more accessible to households across the US. This initiative is part of their [...]
KBio Announces FDA Clearance of IND Application for EV68-228-N for the Treatment of Acute Flaccid Myelitis and the First Patient Dosed in the Phase 1 Study
28/06/2024
• The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for EV68-228-N, a human monoclonal IgG1 against the capsid of enterovirus D68 (EV-D68) designed as an [...]
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
28/06/2024
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our [...]
Fortrea lance un studio d’innovation en IA pour galvaniser les solutions technologiques et humaines afin d’améliorer la réalisation des essais cliniques
28/06/2024
DURHAM, État de Caroline du Nord, 28 juin 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a annoncé aujourd’hui le lancement de son [...]
Le KFSH&RC est à l’avant-garde de la révolution mondiale des soins de santé grâce à l’IA et à la robotique
28/06/2024
RIYAD, Arabie saoudite, 28 juin 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH&RC) est à la pointe de la révolution mondiale de l’IA et de la robotique. Ces avancées [...]
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
28/06/2024
Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, [...]
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
28/06/2024
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- [...]
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
28/06/2024
KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology [...]
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
28/06/2024
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac [...]

Pages